Page 2 - Filgotinib Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated ...

Message : Required fields -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU -- Galapagos webcast presentation tomorrow, 16 December 2...

Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)   -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Devel...